Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Significant Increase in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 199,800 shares, a growth of 25.2% from the March 15th total of 159,600 shares. Based on an average trading volume of 3,420,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 26.1% of the company’s shares are short sold.

Hepion Pharmaceuticals Trading Down 6.1 %

Shares of NASDAQ:HEPA traded down $0.02 during trading on Friday, hitting $0.32. 1,232,914 shares of the company’s stock traded hands, compared to its average volume of 1,027,787. The company has a 50-day moving average price of $3.26 and a 200-day moving average price of $18.46. Hepion Pharmaceuticals has a 52 week low of $0.31 and a 52 week high of $79.98. The company has a market cap of $3.54 million, a price-to-earnings ratio of -0.07 and a beta of 1.79.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.